Agc biologics' heidelberg site supplies drug substance for phase ii studies of valneva's tetravalent shigella vaccine candidate

Seattle & heidelberg, germany--(business wire)--agc biologics, your friendly cdmo expert, today announced a development and manufacturing services agreement with specialty vaccine company valneva se (nasdaq: valn; euronext paris: vla) to supply drug substance for an investigational four-valent shigella bioconjugate vaccine at the cdmo's heidelberg facility. valneva exclusively licensed the vaccine candidate from limmatech biologics ag, which previously worked with agc biologics to establish gmp.
VALN Ratings Summary
VALN Quant Ranking